Clover Health Investments Corp
NASDAQ:CLOV

Watchlist Manager
Clover Health Investments Corp Logo
Clover Health Investments Corp
NASDAQ:CLOV
Watchlist
Price: 2.5 USD 4.6% Market Closed
Market Cap: $1.3B

P/S

0.7
Current
27%
More Expensive
vs 3-y average of 0.5

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
0.7
=
Market Cap
$1B
/
Revenue
$1.9B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
0.7
=
Market Cap
$1B
/
Revenue
$1.9B

Valuation Scenarios

Clover Health Investments Corp is trading above its 3-year average

If P/S returns to its 3-Year Average (0.5), the stock would be worth $1.97 (21% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-21%
Maximum Upside
+261%
Average Upside
97%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 0.7 $2.5
0%
3-Year Average 0.5 $1.97
-21%
5-Year Average 0.6 $2.24
-10%
Industry Average 1.7 $6.47
+159%
Country Average 2.4 $9.03
+261%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
$1B
/
Jan 2026
$1.9B
=
0.7
Current
$1B
/
Dec 2026
$2.9B
=
0.3
Forward
$1B
/
Dec 2027
$3.4B
=
0.3
Forward
$1B
/
Dec 2028
$3.8B
=
0.3
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
US
Clover Health Investments Corp
NASDAQ:CLOV
1.3B USD 0.7 -15.2
US
UnitedHealth Group Inc
NYSE:UNH
320.2B USD 0.7 26.6
US
Anthem Inc
LSE:0HG8
85.8B USD 0.4 15.2
US
Elevance Health Inc
NYSE:ELV
72.4B USD 0.4 12.8
US
Humana Inc
NYSE:HUM
26.2B USD 0.2 22.1
US
Centene Corp
NYSE:CNC
19.1B USD 0.1 -2.9
US
Molina Healthcare Inc
NYSE:MOH
7.8B USD 0.2 16.5
US
Healthequity Inc
NASDAQ:HQY
7B USD 5.4 32.7
US
Magellan Health Inc
F:MAH1
2.2B EUR 0.5 8.5
BR
Odontoprev SA
BOVESPA:ODPV3
8.5B BRL 3.5 14.4
US
Progyny Inc
NASDAQ:PGNY
1.5B USD 1.1 25.2
P/E Multiple
Earnings Growth PEG
US
Clover Health Investments Corp
NASDAQ:CLOV
Average P/E: 19.3
Negative Multiple: -15.2
N/A N/A
US
UnitedHealth Group Inc
NYSE:UNH
26.6
22%
1.2
US
A
Anthem Inc
LSE:0HG8
15.2
10%
1.5
US
Elevance Health Inc
NYSE:ELV
12.8
10%
1.3
US
Humana Inc
NYSE:HUM
22.1
38%
0.6
US
Centene Corp
NYSE:CNC
Negative Multiple: -2.9 N/A N/A
US
Molina Healthcare Inc
NYSE:MOH
16.5
14%
1.2
US
Healthequity Inc
NASDAQ:HQY
32.7
35%
0.9
US
M
Magellan Health Inc
F:MAH1
8.5
N/A N/A
BR
Odontoprev SA
BOVESPA:ODPV3
14.4
4%
3.6
US
Progyny Inc
NASDAQ:PGNY
25.2
35%
0.7

Market Distribution

Lower than 83% of companies in the United States of America
Percentile
17th
Based on 11 520 companies
17th percentile
0.7
Low
0 — 1.2
Typical Range
1.2 — 4.1
High
4.1 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.2
Median 2.4
70th Percentile 4.1
Max 4 613 274.2

Clover Health Investments Corp
Glance View

Market Cap
1.3B USD
Industry
Health Care

Clover Health Investments Corp. embarked on a mission to transform the healthcare landscape with its innovative approach as a next-generation Medicare Advantage insurer. Born out of the need to reduce inefficiencies and enhance care, Clover Health uses its proprietary technology platform, the Clover Assistant, to arm physicians with data-driven insights that facilitate informed decision-making at the point of care. By integrating technology with healthcare delivery, Clover targets not only the evident administrative wastage but also addresses the structural challenges faced by patients and providers alike. This unique integration of digital tools with a traditional insurance model sets Clover apart in an industry ripe for disruption. Revenue for Clover Health primarily comes from Medicare Advantage premiums, where it competes by offering cost-effective plans combined with improved service. The company augments its financial model through government reimbursements tied to patient outcomes and the quality of care. Central to this strategy is the effective use of data analytics to manage patient care, reduce medical costs, and improve customer satisfaction. This alignment of financial incentives—lowering costs while enhancing patient outcomes—fuels Clover’s growth narrative, positioning it as a key player in reshaping how Medicare Advantage operates at the intersection of technology and healthcare delivery.

CLOV Intrinsic Value
2.64 USD
Undervaluation 5%
Intrinsic Value
Price $2.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett